Effect of iptakalim hydrochloride on extracellular matrix of kidney in spontaneously hypertensive rats

Abstract

Abstract: AIM: To investigate the effects of iptakalim hydrochloride (Ipt) on extracellular matrix in SHR renal tissue.METHODS: SHRs at the age of 12-week-old were treated ig with Ipt 1, 3, 9mg·kg^-1·d^-1 ,benazepril 3 mg·kg^-1·d^-1 once a day for 12 weeks.Age-matched WKY rats were used as normal control.The effects of iptakalim on collagen-Ⅳ, MMP-9, TIMP-1 and TGF-β1 expression in SHR kidneys were measured by immunohistochemistry and RT-PCR.RESULTS: After 12 weeks treatment with iptakalim, the expression of MMP-9 mRNA and protein were up-regulated, and those of TGF-β1 , TIMP-1, and Col-Ⅳwere down-regulated in the SHR kidney compared with the untreated controls.CONCLUSION: Iptakalim protects the kidney from hypertensive damage partly by inhibiting TGF-β1 expression and regulating MMP-9 TIMP-1 unbalance in renal tissue, thus promoting ECM degradation, decreasing ECMaccumulation.

Key words: iptakalim hydrochloride, spontaneously hypertensive rats, kidney, extracellular matrix

CLC Number:

XUE Hao, GAO Min, LIU Guo-shu, WANG Hai. Effect of iptakalim hydrochloride on extracellular matrix of kidney in spontaneously hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1122-1128.

References

1 Lenz O, Elliot SJ, Stetler-Stevenson WG.Matrix metalloproteinases in renal development and disease[J].J Am Soc Nephrol,2000;11:574-81
2 Roger M.Mason and nadia abdel wahab.Extracellular matrix metabolism in diabetic nephropathy[J].J Am Soc Nephrol,2003;14:1358-73
3 龙超良, 冯华松, 汪海.盐酸埃他卡林对高血压心脏重构的作用[J].中国药理学通报, 2003;19:48-51
4 龙超良, 肖文彬, 汪海.盐酸埃他卡林的降压作用及对高血压血管重构的影响[J].高血压杂志, 2003;11:248-50
5 Schnaper HW.Balance between matrix synthesis and degradation:a determinant of glomerulosclerosis[J].Pediatr Nephrol,1995;9:104-11
6 Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C.Regression of renal vascular and glomerular fibrosis:role of angiotensin II receptor antagonism and matrix metalloproteinases[J].J Am Soc Nephrol, 2003;14:1132-44
7 Schaefer L, Han X, August C, Matzkies F, Lorenz T, Schaefer RM.Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats[J].Diabetologia, 1997;40:1035-43
8 McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK,Gilbert RE.Decreased matrix degradation in diabetic nephropathy:Effects of ACE inhibition on the expression and activities of matrix metalloproteinases[J].Diabetologia, 2002;45:268-75
9 Shankland SJ, Ly H, Thai K, Scholey JW.Glomerular expression of tissue inhibitor of metalloproteinase (TIMP-1) in normal and diabetic rats[J].J Am Soc Nephrol, 1996;7:97-104
10 Singhal PC, Sagar S, Garg P.Simulated glomerular pressure modulates mesangial cell 72 KD metalloproteinase activity[J].Connect Tissue Res, 1996;33:257-63
11 Douthwaite JA, Johnson TS, Haylor JL, Watson P, El Nahas AM.Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating proteins[J].J Am Soc Nephrol, 1999;10:2109-19
12 Peters H, Border WA, Noble NA.Targeting TGF-beta overexpression in renal disease:maximizing the antifibrotic action of angiotensin II blockade[J].Kidney Int, 1998;54:1570-80

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[3]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[4]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[5]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[6]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[7]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[8]	ZHU Xinru, HUANG Xin. Roles of indoxyl sulfate in complications of chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 672-679.
[9]	ZHAN Zhuqin, BAI Haitao. Effects of different doses of dexamethasone on angiotensin II, its receptors and NO levels in septic kidney injury rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 995-1004.
[10]	WANG Xiangyi, SHENG Jie, WANG Xiu, GUO Yan, CHEN Zhiwu. Distribution of deuterosuccinylcholine chloride in rats determined by UPLC-MS/MS method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 271-277.
[11]	CHEN Jia, LIU Qingwu, HE Xiujuan, LI Ping. Research progress of extracellular matrix on skin wound repair [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 716-720.
[12]	GAO Yiwen, ZHANG Nan, LV Chanmei, YANG Xuanmei, YUE Guihua. Effects of Huanglianjiedu Decoction on vascular endothelial NO pathway in young spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 248-253.
[13]	CAI Mingmin，YAO Lan，ZHANG Jingwei，ZHOU Fang，WANG Guangji. Research progress in drug-induced acute kidney injury based on mitochondrial damage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 578-585.
[14]	FANG Jingjing, TAO Jing, HUANG Qin, SHI Chaolu, YAN Biqing, GAI Lei, LI Xuguang. Effects of platelet activation on renal tubular epithelial cells in sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 283-289.
[15]	YANG Xiaohu, LIAN Hong, YU Yang, YUE Yingxing, ZHANG Yong. Protective effect of Naoxintong capsule on kidney injury in spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 875-880.